<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115669</url>
  </required_header>
  <id_info>
    <org_study_id>21E1573/WFP_001</org_study_id>
    <nct_id>NCT05115669</nct_id>
  </id_info>
  <brief_title>Safety &amp; Effectiveness of Wortie Freeze Plus in Common and Plantar Warts</brief_title>
  <official_title>Prospective, Open Clinical Investigation to Evaluate the Effectiveness and Safety of Wortie® Freeze Plus in the Treatment of Common Warts and Plantar Warts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karo Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karo Pharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Post-Market clinical Follow-up investigation to evaluate the safety and performed&#xD;
      of the medical device Wortie Freeze Plus in the treatment of common and plantar warts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with cured wart after maximun 3 treatments evaluate by the investigator</measure>
    <time_frame>Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with cured wart after 1, 2 and 3 treatments evaluated by the investigator common and plantar warts after 1, 2 and 3 treatments as assessed by the investigator</measure>
    <time_frame>Day 14, Day 28, Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with improved aspect of the wart after 1, 2 and 3 treatments evaluated by the investigator</measure>
    <time_frame>Day 14, Day 28, Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean frostbite area diameter after each treatment</measure>
    <time_frame>Day 0, Day 14, Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects satisfied with the treatment by answering a questionnaire at the study end</measure>
    <time_frame>Day 14, Day 28, Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Illustration of the skin aspect by pictures before and after each treatment</measure>
    <time_frame>Day 0, Day 14, Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean subject' pain during treatment evaluated using a using a 11-item (0-10) Numerical Rating Scale</measure>
    <time_frame>Day 0, Day 14, Day 28</time_frame>
    <description>0= no pain; 10= worst possible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject tolerability evaluated at the study end by the investigator using a 4-item (0-3) Numerical scale</measure>
    <time_frame>Day 14,Day 28, Day 42</time_frame>
    <description>0=bad tolerance; 1= moderate tolerance; 2= good tolerance; 3 = very good tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of adverse events throughout the study</measure>
    <time_frame>Day 0, Day 14, Day 28, Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Common Wart</condition>
  <condition>Plantar Wart</condition>
  <arm_group>
    <arm_group_label>Wortie freeze plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryogenic medical device (dimethylether-based product) + conductive gel + protective foam plasters.&#xD;
Up to 3 applications one every 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wortie freeze plus</intervention_name>
    <description>treatment of common and plantar warts</description>
    <arm_group_label>Wortie freeze plus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy subjects.&#xD;
&#xD;
          2. Sex: male or female.&#xD;
&#xD;
          3. Age: 12 years old and above.&#xD;
&#xD;
          4. Subjects presenting at least 1 common wart (present since less than 6 months) on the&#xD;
             fingers or back of the hands, and/or plantar wart (40-60% subjects with common wart)&#xD;
             of a size less than 1 cm.&#xD;
&#xD;
          5. Subject, including minors having more than 12 years old, having given freely and&#xD;
             expressly his/her informed consent.&#xD;
&#xD;
          6. Minor whose legally designated representative have given their free and express&#xD;
             informed consent.&#xD;
&#xD;
          7. Subject affiliated to a health social security system.&#xD;
&#xD;
          8. Female of childbearing potential should use a contraceptive regimen recognized as&#xD;
             effective since at least 12 weeks before screening visit, during all the study and at&#xD;
             least 1 month after the study end&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing woman or planning a pregnancy during the study.&#xD;
&#xD;
          2. Subject who had been deprived of their freedom by administrative or legal decision.&#xD;
&#xD;
          3. Major subject who is under guardianship or who is not able to express his consent.&#xD;
&#xD;
          4. Subject in a social or sanitary establishment.&#xD;
&#xD;
          5. Subject suspected to be non-compliant according to the Investigator's judgment&#xD;
&#xD;
          6. Subject suffering from a severe or progressive disease or any other pathology that may&#xD;
             interfere with the evaluation of the study results.&#xD;
&#xD;
          7. Subject with a cutaneous disease other than common warts, on the studied zone.&#xD;
&#xD;
          8. Subject with a known allergy to one of the components of the investigational device or&#xD;
             conductive gel.&#xD;
&#xD;
          9. Subject who has diabetes.&#xD;
&#xD;
         10. Subject having problems with blood circulation or having a blood clotting condition.&#xD;
&#xD;
         11. Subject with immune deficiency or autoimmune disease.&#xD;
&#xD;
         12. Subject presenting more than 10 warts on the body&#xD;
&#xD;
         13. Subject presenting bleeding warts.&#xD;
&#xD;
         14. Subject presenting birthmarks, moles, warts with hairs growing from them, or any other&#xD;
             spots on the treated and surrounding area.&#xD;
&#xD;
         15. Subject having a sensitive, inflamed, infected, irritated, red, damaged, cut, grazed,&#xD;
             diseased or itchy skin on or around the treated zone.&#xD;
&#xD;
         16. Subject presenting genital warts, flat warts, filiform warts, periungual warts or&#xD;
             warts with hairs growing from them.&#xD;
&#xD;
         17. Subject presenting 2 or more warts adjacent to each other&#xD;
&#xD;
         18. Subject undergoing a topical treatment on the test area or a systemic treatment:&#xD;
             anti-inflammatory medication and/or antihistamines during the 2 weeks prior to&#xD;
             screening and during the study; or corticosteroids during the 2 weeks prior to&#xD;
             screening and during the study; or retinoids and/or immunosuppressors during the 3&#xD;
             months prior to screening and during the study; or any medication stabilized for less&#xD;
             than a month&#xD;
&#xD;
         19. Subject who received a treatment of any type on the selected wart during the previous&#xD;
             6 months.&#xD;
&#xD;
         20. Subject having started or changed her oral contraceptive or any other hormonal&#xD;
             treatment during the three previous months&#xD;
&#xD;
         21. Intensive exposure to sunlight or UV-rays on the studied zone within the previous&#xD;
             month and/or foreseen during the study.&#xD;
&#xD;
         22. Subject planning to change her/his life habits during the study.&#xD;
&#xD;
         23. Subject with excessive consumption of alcohol (more than 2 glasses of wine per day)&#xD;
             and/or tobacco (more than 10 cigarettes per day).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnieszka Cegielska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermascan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Arribas</last_name>
    <phone>010-330 23 10</phone>
    <email>maria.arribas@karopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eurofins Dermascan Poland</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Foot Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

